^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Hodgkin Lymphoma

    Related cancers:
    1d
    WF-1804CD: Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors (clinicaltrials.gov)
    P=N/A, N=600, Completed, Wake Forest University Health Sciences | Active, not recruiting --> Completed
    Trial completion
    3d
    Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Aug 2038 --> Nov 2039 | Trial primary completion date: Sep 2027 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    TT11
    3d
    A Rare Case of Bullous Pemphigoid Triggered by Overlapping Immune Dysregulation From HIV and Hodgkin Lymphoma: A Case Report. (PubMed, Cureus)
    Management was complicated by the patient's immunosuppression, limiting the use of systemic corticosteroids and delaying wound healing. This case highlights an uncommon clinical intersection of BP, advanced HIV, and Hodgkin lymphoma.
    Journal
    |
    CD4 (CD4 Molecule)
    3d
    FIL_PRIORITY: PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma: a Randomized, Phase III, Non-inferiority studY (PRIORITY Study) (clinicaltrials.gov)
    P3, N=518, Not yet recruiting, Fondazione Italiana Linfomi - ETS
    New P3 trial • Head-to-Head
    3d
    NCI-2020-09704: Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=39 --> 22
    Enrollment closed • Enrollment change
    |
    Xpovio (selinexor)
    6d
    Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 19 | Trial completion date: Mar 2043 --> Jul 2040 | Trial primary completion date: Mar 2027 --> Aug 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)
    |
    ALK positive
    |
    cyclophosphamide • fludarabine IV • rimiducid (AP1903)
    8d
    Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    busulfan
    8d
    Nivo40-AVD for Advanced Classic Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=54, Recruiting, National Medical Research Radiological Centre of the Ministry of Health of Russia | Trial completion date: Jan 2032 --> Jan 2029 | Trial primary completion date: Jan 2029 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • doxorubicin hydrochloride • dacarbazine • vinblastine
    9d
    Whole Exome Sequencing for the Identification of Mutations in Bone Marrow CD34+Cells in Hodgkin Lymphoma. (PubMed, Curr Issues Mol Biol)
    WES revealed significantly mutated genes, most of which were associated with the physiological activation of lymphoma cells. This finding contributed to the identification of novel gene variants that might impact on the function of BM CD34+ cells in cHL patients.
    Journal
    |
    KMT2C (Lysine Methyltransferase 2C) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD34 (CD34 molecule) • MUC4 (Mucin 4, Cell Surface Associated) • MMP9 (Matrix metallopeptidase 9) • TCF19 (Transcription Factor 19)
    11d
    Single-Cell Profiling of HDAC Inhibitor-Induced EBV Lytic Heterogeneity Defines Abortive and Refractory States in B Lymphoblasts. (PubMed, bioRxiv)
    We therefore characterized the impact of pan-HDAC inhibitor, panobinostat, and class I HDAC inhibitor, nanatinostat, on the growth, survival, and lytic reactivation of four EBV-positive cell lines: P3HR1-ZHT BL, Jijoye BL, IBL-1 immunoblastic lymphoma, and de novo infection derived lymphoblastoid cell lines (LCL). Single-cell RNA sequencing provided evidence of upregulated immune signaling pathways in this abortive lytic population. This study provides in depth characterization of lytic reactivation with a biologically relevant stimulus.
    Journal • IO biomarker
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Farydak (panobinostat) • nanatinostat (VRx-3996)
    13d
    Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2) (clinicaltrials.gov)
    P=N/A, N=222, Completed, University Hospital, Bordeaux | Not yet recruiting --> Completed | Initiation date: Sep 2025 --> Feb 2025
    Trial completion • Trial initiation date
    |
    Adcetris (brentuximab vedotin) • bendamustine